Tag Archives: Spero Therapeutics

H.C. Wainwright Sticks to Their Buy Rating for Spero Therapeutics (SPRO)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $40.00. The company’s shares closed last Friday at $14.50. According to TipRanks.com, Selvaraju is

Oppenheimer Believes Spero Therapeutics (NASDAQ: SPRO) Won’t Stop Here

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Spero Therapeutics (SPRO – Research Report) today and set a price target of $19.00. The company’s shares closed last Friday at $14.02, close to its 52-week high of $14.60. According to

Spero Therapeutics (SPRO) Receives a Buy from Oppenheimer

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $20.00. The company’s shares closed last Tuesday at $12.45. According to TipRanks.com, DeGeeter is a

Analysts Offer Insights on Healthcare Companies: Spero Therapeutics (NASDAQ: SPRO) and Eiger Biopharmaceuticals (NASDAQ: EIGR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spero Therapeutics (SPRO – Research Report) and Eiger Biopharmaceuticals (EIGR – Research Report) with bullish sentiments. Spero Therapeutics (SPRO) In a report

Spero Therapeutics (SPRO) Gets a Buy Rating from Oppenheimer

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Spero Therapeutics (SPRO – Research Report), with a price target of $20.00. The company’s shares closed last Monday at $5.35, close to its 52-week low of

Spero Therapeutics (SPRO) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report) today and set a price target of $35.00. The company’s shares closed last Monday at $8.89, close to its 52-week low of $7.99. According